Biopharma GettyImages-523791776.jpg
Our Work

Latham Advises Global Medical Device Leader on US$50 Million Series D Fundraising of TriCares

July 31, 2024
Cross-border team advises firm on strategic investment in French medtech startup.

Latham & Watkins has advised a global medical device leader on the US$50 million series D financing round of TriCares, which has operations in France and Germany.

TriCares is on a mission to revolutionize healthcare by innovation and proximity to patients. It is developing and delivering a breakthrough tricuspid heart valve replacement system that brings hope and improves quality of life for those in need.

The Latham team was led by Paris corporate partner Pierre-Louis Clero and Boston corporate partner Julie Scallen, with Paris counsel Xavier Nassoy and Boston counsel Stefanie Vincent, with Paris associates Jacek Urban, Lorraine Dorval, and Giovanni Novi, and Düsseldorf associate Henrietta Ditzen. Advice was also provided on employment and benefits matters by Paris partner Matthias Rubner, with Paris associate Yanis Gaoua and Munich associate Kristina Hufnagel; on tax matters by Paris partner Olivia Rauch-Ravise and Washington, D.C. partner Nicholas DeNovio, with Paris counsel Cécile Mariotti and Washington, D.C. associate Abigail Friedman; on IP, IT, and commercial contract matters by Paris partner Jean-Luc Juhan, with Paris associate Daniel Martel and Frankfurt associate Daniela Jaeger; and on life sciences matters by Paris partner Eveline Van Keymeulen, with Washington, D.C. counsel Chad Jennings and Paris associate Jeanne Fabre.

Endnotes